$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

$bcrx Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000117184322003423 Filed on May 09, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$49.92M	$19.06M
YoY Change	161.94%	295.17%
Cost Of Revenue	$236.0K	$5.923M
YoY Change	-96.02%
Gross Profit	$49.69M	$13.14M
YoY Change	278.25%	172.36%
Gross Profit Margin	99.53%	68.92%
Selling, General & Admin	$34.28M	$22.11M
YoY Change	55.02%	39.39%
% of Gross Profit	69.0%	168.35%
Research & Development	$65.36M	$42.44M
YoY Change	54.02%	42.08%
% of Gross Profit	131.54%	323.04%
Depreciation & Amortization	$317.0K	$178.0K
YoY Change	78.09%	-18.35%
% of Gross Profit	0.64%	1.36%
Operating Expenses	$99.64M	$64.55M
YoY Change	54.37%	41.15%
Operating Profit	-$49.96M	-$51.38M
YoY Change	-2.76%	25.38%
Interest Expense	$23.84M	$12.90M
YoY Change	84.73%	323.5%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$73.92M	-$64.28M
YoY Change	14.99%	70.97%
Income Tax	$279.0K	$0.00
% Of Pretax Income
Net Earnings	-$74.20M	-$64.28M
YoY Change	15.42%	70.97%
Net Earnings / Revenue	-148.62%	-337.29%
Basic Earnings Per Share	-$0.40	-$0.36
Diluted Earnings Per Share	-$401.3K	-$362.5K
COMMON SHARES
Basic Shares Outstanding	184.9M shares	177.2M
Diluted Shares Outstanding	184.9M	177.3M

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$443.5M	$240.4M
YoY Change	84.5%	112.6%
Cash & Equivalents	$395.5M	$226.9M
Short-Term Investments	$47.96M	$13.45M
Other Short-Term Assets	$15.69M	$9.900M
YoY Change	58.45%	45.59%
Inventory	$16.14M	$5.113M
Prepaid Expenses
Receivables	$36.42M	$18.39M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$511.7M	$273.8M
YoY Change	86.91%	118.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.799M	$7.035M
YoY Change	25.07%	-3.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00
YoY Change
Other Assets	$7.207M	$3.625M
YoY Change	98.81%	-4.88%
Total Long-Term Assets	$16.01M	$10.66M
YoY Change	50.15%	-3.8%
TOTAL ASSETS
Total Short-Term Assets	$511.7M	$273.8M
Total Long-Term Assets	$16.01M	$10.66M
Total Assets	$527.7M	$284.4M
YoY Change	85.54%	108.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.88M	$13.53M
YoY Change	2.6%	34.47%
Accrued Expenses	$63.58M	$32.72M
YoY Change	94.33%	62.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$30.00M
YoY Change	-100.0%	1.01%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$81.02M	$101.2M
YoY Change	-19.94%	9.17%
LONG-TERM LIABILITIES
Long-Term Debt	$140.2M	$123.0M
YoY Change	13.98%	237.09%
Other Long-Term Liabilities	$6.457M	$3.900M
YoY Change	65.56%	5.41%
Total Long-Term Liabilities	$140.2M	$123.0M
YoY Change	13.98%	206.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$81.02M	$101.2M
Total Long-Term Liabilities	$140.2M	$123.0M
Total Liabilities	$221.3M	$224.2M
YoY Change	-1.33%	68.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.282B	-$1.088B
YoY Change	17.83%	23.85%
Common Stock	$1.856M	$1.777M
YoY Change	4.45%	15.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$164.2M	-$74.99M
YoY Change
Total Liabilities & Shareholders Equity	$527.7M	$284.4M
YoY Change	85.54%	108.24%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$74.20M	-$64.28M
YoY Change	15.42%	70.97%
Depreciation, Depletion And Amortization	$317.0K	$178.0K
YoY Change	78.09%	-18.35%
Cash From Operating Activities	-$77.80M	-$61.01M
YoY Change	27.52%	162.06%
INVESTING ACTIVITIES
Capital Expenditures	-$406.0K	-$100.0K
YoY Change	306.0%	-16.67%
Acquisitions
YoY Change
Other Investing Activities	-$38.07M	$14.77M
YoY Change	-357.73%	36.25%
Cash From Investing Activities	-$38.47M	$14.67M
YoY Change	-362.2%	36.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$7.356M	$2.900M
YoY Change	153.66%	990.23%
NET CHANGE
Cash From Operating Activities	-$77.80M	-$61.01M
Cash From Investing Activities	-$38.47M	$14.67M
Cash From Financing Activities	$7.356M	$2.900M
Net Change In Cash	-$108.9M	-$43.44M
YoY Change	150.65%	253.41%
FREE CASH FLOW
Cash From Operating Activities	-$77.80M	-$61.01M
Capital Expenditures	-$406.0K	-$100.0K
Free Cash Flow	-$77.39M	-$60.91M
YoY Change	27.06%	162.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	185583896
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	185572000
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	185572000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	184350000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	184350000
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1108
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	3984000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28699000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	395504000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	504389000	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	3354000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	3345000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	47964000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	3212000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36415000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	29413000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	16144000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	15791000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12333000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9986000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	511714000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	566136000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8799000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8714000	USD
CY2022Q1	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	6829000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7207000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6472000	USD
CY2022Q1	us-gaap	Assets Assets	527720000	USD
CY2021Q4	us-gaap	Assets Assets	588151000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	13881000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	27808000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	63584000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	72670000	USD
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1471000	USD
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1421000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2081000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1819000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	81017000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	103718000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6457000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5962000	USD
CY2022Q1	bcrx	Future Royalties Payable FutureRoyaltiesPayable	464225000	USD
CY2021Q4	bcrx	Future Royalties Payable FutureRoyaltiesPayable	449375000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	140236000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	136082000	USD
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	1856000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1843000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1115443000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1098498000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	186000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	177000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1281700000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1207504000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-164215000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-106986000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	527720000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	588151000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	49923000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	19059000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	236000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5923000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65360000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42435000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34282000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22114000	USD
CY2022Q1	bcrx	Royalty Expense Reversal Of Expense RoyaltyExpenseReversalOfExpense	2000	USD
CY2021Q1	bcrx	Royalty Expense Reversal Of Expense RoyaltyExpenseReversalOfExpense	-36000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	99880000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	70436000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-49957000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-51377000	USD
CY2022Q1	bcrx	Interest And Other Income Loss InterestAndOtherIncomeLoss	54000	USD
CY2021Q1	bcrx	Interest And Other Income Loss InterestAndOtherIncomeLoss	26000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	23837000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	12904000	USD
CY2022Q1	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-177000	USD
CY2021Q1	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-29000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-73917000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64284000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	279000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-74196000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-64284000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	78000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	178000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-69000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-74187000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-64105000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	184898000
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	177343000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-74196000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-64284000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	317000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	178000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9601000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5479000	USD
CY2022Q1	bcrx	Noncash Interest Expense And Amortization Of Debt Issuance Costs NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts	19003000	USD
CY2021Q1	bcrx	Noncash Interest Expense And Amortization Of Debt Issuance Costs NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts	11027000	USD
CY2022Q1	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	30000	USD
CY2021Q1	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	14000	USD
CY2022Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	7048000	USD
CY2021Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	261000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	354000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1927000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2320000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9850000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-22908000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7373000	USD
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2021Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1877000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	75000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	255000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-77800000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-61011000	USD
CY2022Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	406000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-19262000	USD
CY2021Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	99000	USD
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	38066000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	-0	USD
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	14771000	USD
CY2022Q1	bcrx	Realized Gain Loss On Sale Of Investments Investing Activities RealizedGainLossOnSaleOfInvestmentsInvestingActivities	-0	USD
CY2021Q1	bcrx	Realized Gain Loss On Sale Of Investments Investing Activities RealizedGainLossOnSaleOfInvestmentsInvestingActivities	-1000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38472000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14673000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7356000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2900000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7356000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2900000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-108876000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-43438000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	507734000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	274348000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	398858000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	230910000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-106986000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-74196000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	9000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1504000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5853000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9601000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-164215000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-64284000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	179000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	723000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2177000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5479000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-74988000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options, the ORLADEYO and Factor D inhibitors royalty financing obligations and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23741000
CY2021Q1	us-gaap	Advertising Expense AdvertisingExpense	1404000	USD
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	23837000	USD
CY2021Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	12904000	USD
CY2022Q1	bcrx	Amortization Of Debt Financing Costs And Original Issue Discounts AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts	167000	USD
CY2021Q1	bcrx	Amortization Of Debt Financing Costs And Original Issue Discounts AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts	58000	USD
CY2021Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	-1000	USD
CY2022Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	49923000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	19059000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	47925000	USD
CY2022Q1	bcrx	Available For Sale Debt Securities Accrued Interest AvailableForSaleDebtSecuritiesAccruedInterest	120000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	82000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	47964000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	9989000	USD
CY2021Q4	bcrx	Available For Sale Debt Securities Accrued Interest AvailableForSaleDebtSecuritiesAccruedInterest	65000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	10041000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	47964000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	3212000	USD
CY2022Q1	bcrx	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Two DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo	0	USD
CY2021Q4	bcrx	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Two DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo	6829000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	47964000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	10041000	USD
CY2022Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	1932000	USD
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1980000	USD
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5269000	USD
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5658000	USD
CY2022Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	10434000	USD
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	9669000	USD
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	694000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	709000	USD
CY2022Q1	us-gaap	Inventory Gross InventoryGross	16397000	USD
CY2021Q4	us-gaap	Inventory Gross InventoryGross	16036000	USD
CY2022Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	253000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	245000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	16144000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	15791000	USD
CY2021Q4	bcrx	Future Royalties Payable FutureRoyaltiesPayable	449375000	USD
CY2022Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	34000	USD
CY2022Q1	bcrx	Non Cash Interest Expense On Royalty Financing Obligation NonCashInterestExpenseOnRoyaltyFinancingObligation	19649000	USD
CY2022Q1	bcrx	Royalties Revenues Paid And Payable RoyaltiesRevenuesPaidAndPayable	-4765000	USD
CY2022Q1	bcrx	Future Royalties Payable FutureRoyaltiesPayable	464225000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1036	pure
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	594000	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	452000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2081000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1819000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6457000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5962000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8538000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	7781000	USD
CY2022Q1	bcrx	Operating Lease Rightofuse Asset Accumulated Amortization OperatingLeaseRightofuseAssetAccumulatedAmortization	3019000	USD
CY2021Q4	bcrx	Operating Lease Rightofuse Asset Accumulated Amortization OperatingLeaseRightofuseAssetAccumulatedAmortization	2626000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	574000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	440000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1820000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2190000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1641000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1348000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	617000	USD
CY2022Q1	bcrx	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	6734000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14350000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5812000	USD
CY2020Q2	bcrx	Maximum Aggregate Offering Price MaximumAggregateOfferingPrice	500000000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9601000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5479000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	109635000	USD
CY2022Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized For Remainder Of Fiscal Year EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear	28801000	USD
CY2022Q1	bcrx	Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Next Year EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear	33073000	USD
CY2022Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo	30267000	USD
CY2022Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree	17094000	USD
CY2022Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour	400000	USD
CY2022Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	115000
CY2021Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	193000

Files In Submission

Name	View Source	Status
0001171843-22-003423-index-headers.html	Edgar Link	pending
0001171843-22-003423-index.html	Edgar Link	pending
0001171843-22-003423.txt	Edgar Link	pending
0001171843-22-003423-xbrl.zip	Edgar Link	pending
bcrx-20220331.xsd	Edgar Link	pending
bcrx-20220331_cal.xml	Edgar Link	unprocessable
bcrx-20220331_def.xml	Edgar Link	unprocessable
bcrx-20220331_lab.xml	Edgar Link	unprocessable
bcrx-20220331_pre.xml	Edgar Link	unprocessable
bcrx20220331_10q.htm	Edgar Link	pending
bcrx20220331_10q_htm.xml	Edgar Link	completed
exh101_01.jpg	Edgar Link	pending
exh101_02.jpg	Edgar Link	pending
ex_366876.htm	Edgar Link	pending
ex_366877.htm	Edgar Link	pending
ex_366878.htm	Edgar Link	pending
ex_366879.htm	Edgar Link	pending
ex_371288.htm	Edgar Link	pending
ex_371289.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2022 Q1 Form 10-Q Financial Statement

#000117184322003423 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2022 Q1 Form 10-Q Financial Statement

#000117184322003423 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx